Preclinical HER-2 Vaccines: From Rodent to Human HER-2
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 151
- https://doi.org/10.3389/fonc.2013.00151
Abstract
Effective prevention of human cancer with vaccines against viruses, such as HBV and HPV, raises the question whether also non-virus related tumors could be prevented with immunological means. Studies in HER-2-transgenic mice showed that powerful anti-HER-2 vaccines, could almost completely prevent the onset of mammary carcinoma. Protective immune responses were orchestrated by T cells and their cytokines, and effected by antibodies against HER-2 gene product p185. Analogous findings were reported in a variety of other cancer immunoprevention systems, thus leading to the definition of oncoantigens, optimal target antigens that are causally involved in carcinogenesis and cancer progression. Prophylactic HER-2 vaccines were also effective in preventing metastasis outgrowth, indicating that concepts and approaches developed for cancer immunoprevention could prove fruitful in cancer immunotherapy as well. The availability of cancer-prone mice carrying a human HER-2 transgene is now fostering the design of novel vaccines against human p185. A further bridge toward human cancer was recently provided by novel immunodeficient models, like Rag2−/−;Il2rg−/− mice, which are permissive for metastatic spread of human HER-2+ cancer cells and can be engrafted with a functional human immune system, allowing for the first time the study of vaccines against oncoantigens to elicit human immune responses against human cancer cells in vivo.Keywords
This publication has 65 references indexed in Scilit:
- 2011: the immune hallmarks of cancerCancer Immunology, Immunotherapy, 2011
- Humanized mouse models to study human diseasesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2010
- Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up StudyJNCI Journal of the National Cancer Institute, 2009
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational ResearchClinical Cancer Research, 2009
- Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumorsCancer Immunology, Immunotherapy, 2008
- Role of exon-16-deleted HER2 in breast carcinomasEndocrine-Related Cancer, 2006
- Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary CarcinomaThe American Journal of Pathology, 2005
- Genetic immunization against neu /erbB2 transgenic breast cancerCancer Immunology, Immunotherapy, 1998
- Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic MiceThe Journal of Experimental Medicine, 1998
- Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.1994